Trial expected to support registration in the U.S. and European Union Sandoz continues to advance biosimilar pipeline with seven Phase III trials across five molecules Global program underscores Sandoz’s leadership in biosimilars Holzkirchen, Germany, 1-7-2013 — /europawire.eu/ — Sandoz, the global … Read the full press release →
Posted in Business, Healthcare, Pharma & Biotech, Science, Switzerland
Tagged Alan Menter, Ameet Mallik, Baylor University Medical Center, Dallas, Enbrel, etanercept, Germany, Holzkirchen, International Psoriasis Council, M.D., Mark McCamish, Ph.D., Sandoz, United States